Drug manufacturers keep investors happy |

Drug manufacturers keep investors happy

The Associated Press

Investors remained in a record-setting mood Tuesday, edging the Dow Jones industrial average and Standard & Poor’s 500 index to their latest all-time highs.

Pharmaceutical and medical equipment companies led the broad pickup in stocks, extending gains for the S&P 500 and Dow. The Nasdaq notched its first gain this week.

A positive outlook from homebuilders and encouraging news from Japan and Germany helped lift markets.

The rally builds on a market rebound in recent weeks powered by strong corporate earnings and easing concerns among investors about the spread of Ebola and economic growth overseas.

“We’ve gotten good news on all of the worries since mid-October, and we had much better-than-expected earnings,” said Kate Warne, an investment strategist at Edward Jones. “As a result, it’s not surprising we’re seeing a series of record highs.”

The major stock indexes opened flat Monday but quickly began to rise.

Germany’s ZEW measure of investor sentiment showed an improvement in November after 10 months of declines, allaying worries about a slowing economy and lifting European markets.

Developments in Japan, whose economy slipped into recession in the third quarter, provided some relief.

Tokyo’s benchmark Nikkei index rose 2.2 percent amid expectations, later confirmed, that Japan’s government will delay a sales tax hike that was planned for next year.

Stocks also got a boost from an increase in a measure of homebuilders’ confidence, which rebounded in November as sales expectations and buyer traffic improved.

The indexes continued to build on their gains throughout the day as investors piled into health care stocks. Pharmaceutical giant Actavis led all stocks in the S&P 500, vaulting 8.7 percent. Medical device maker Medtronic climbed 3.3 percent.

The energy sector lagged the rest of the market as the price of oil resumed its slide.

All told, the S&P 500 index added 10.48 points, or 0.5 percent, to 2,051.80. Its previous closing high was set Monday.

The Dow rose 40.07 points, or 0.2 percent, to 17,687.82. That’s just 0.2 percent higher than its most recent record close on Thursday.

The Nasdaq composite gained 31.44 points, or 0.7 percent, to 4,702.44.

Nine of the 10 sectors in the S&P 500 notched gains, led by health care stocks. The sector is up 23.5 percent this year. Telecommunications stocks declined.

On Oct. 15 the S&P 500 nearly fell into a “correction,” a trading term for a drop of 10 percent or more from a recent peak. The market has mostly risen since then.

The rise in Actavis occurred a day after the company agreed to buy Botox-maker Allergan for $66 billion. Actavis rose $21.66 to $269.60.

“Actavis is up strong, so that suggests it’s a better take on the merger deal, as people get more into the details of it,” Warne said.

With the bulk of earnings season over, investors are looking ahead to how companies will fare this holiday season.

“The broad equity market is in holiday mode,” said Terry Sandven, chief equity strategist at U.S. Bank Wealth Management. “I don’t see the market moving meaningfully higher or lower in the near term until we get greater visibility on what consumers are going to do in the holiday season.”

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.